Cantor Fitzgerald Reiterates Overweight Rating for ALX Oncology (NASDAQ:ALXO)

ALX Oncology (NASDAQ:ALXOGet Rating)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for ALX Oncology’s FY2022 earnings at ($3.23) EPS and FY2023 earnings at ($3.93) EPS.

ALXO has been the topic of several other reports. Stifel Nicolaus dropped their price target on ALX Oncology from $35.00 to $16.00 in a research report on Monday, June 6th. Credit Suisse Group lowered their price objective on ALX Oncology from $43.00 to $38.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.83.

ALX Oncology Stock Performance

ALXO opened at $10.58 on Wednesday. The business has a 50 day moving average price of $12.29 and a 200 day moving average price of $12.23. The firm has a market cap of $431.10 million, a P/E ratio of -3.89 and a beta of 1.84. ALX Oncology has a twelve month low of $5.82 and a twelve month high of $79.00.

Institutional Trading of ALX Oncology

Several institutional investors have recently bought and sold shares of the stock. Federated Hermes Inc. boosted its stake in ALX Oncology by 744.2% in the 2nd quarter. Federated Hermes Inc. now owns 456,753 shares of the company’s stock valued at $3,695,000 after buying an additional 402,646 shares in the last quarter. Legal & General Group Plc boosted its stake in ALX Oncology by 40.6% in the second quarter. Legal & General Group Plc now owns 5,309 shares of the company’s stock worth $43,000 after purchasing an additional 1,534 shares in the last quarter. ExodusPoint Capital Management LP acquired a new position in ALX Oncology in the second quarter worth $1,515,000. Goldman Sachs Group Inc. boosted its stake in ALX Oncology by 15.5% in the second quarter. Goldman Sachs Group Inc. now owns 247,743 shares of the company’s stock worth $2,004,000 after purchasing an additional 33,257 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in ALX Oncology in the second quarter worth $308,000. Institutional investors and hedge funds own 88.98% of the company’s stock.

About ALX Oncology

(Get Rating)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.

See Also

Analyst Recommendations for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.